AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 1 analysts
Fundamentals
Fundamentals institutional score is 92 using growth durability 92.2.
Valuation
Valuation institutional score is 68 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 25 using mean target upside -12.2%; dispersion penalty 0; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 62 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and valuation provide support, while analyst consensus and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 2.9% above historical median. Valuation is stable — currently in the fair zone (z-score: +0.13). Confidence: 89%.
Live forward EPS implies next-12-month EPS of ₹10.00. Applying the stock's normalized valuation corridor produces a fair range of ₹245.40 to ₹288.00, with base value near ₹261.40 (+68.7% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹10.00
Forward P/E
15.5x
Base Fair Value
₹261.40
Fair Range
₹245.40 - ₹288.00
Upside To Base
+68.7%
Estimate Source
Live forward EPS
Growth Estimate
+64.9%
5Y Average
26.40
Current
26.91
Overvalued
28.80
Undervalued
24.54
5Y Average
15.96
Current
16.27
Overvalued
17.61
Undervalued
14.76
5Y Average
2.54
Current
2.59
Overvalued
2.92
Undervalued
2.16
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
GUJARAT KIDNEY N SUP SP L GKSLHospitals & Diagnostic Centres | +212.6% | 18.9% | 54.7x Undervalued | -33% vs avg | +27.4% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 55.2x Undervalued | -32% vs avg | +9.7% |
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 65.4x Undervalued | -19% vs avg | -3.4% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.2x Undervalued | -44% vs avg | +1.0% |
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 138.3x Premium | +70% vs avg | +39.5% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 68.4x Undervalued | -16% vs avg | +6.3% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 157.7x Premium | +94% vs avg | +9.1% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 64.9x Undervalued | -20% vs avg | +12.1% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹126 CrJun 2026Latest net profit
₹13 CrJun 2026Latest EPS
₹1.55Jun 2026Net margin
19.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 96 | 108 | 97 | 99 | 98 | 106 | 102 | 101 | 107 | 119 | 120 | 126 | 126 |
| Expenses + | 77 | 83 | 76 | 76 | 80 | 82 | 81 | 81 | 90 | 96 | 99 | 103 | 102 |
| Operating Profit | 19 | 25 | 21 | 23 | 18 | 23 | 21 | 21 | 17 | 23 | 21 | 23 | 24 |
| OPM % | 20% | 23% | 22% | 23% | 18% | 22% | 21% | 20% | 16% | 19% | 17% | 18% | 19% |
| Other Income + | 1 | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 |
| Interest | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | 14 | 19 | 16 | 18 | 15 | 21 | 18 | 16 | 11 | 15 | 13 | 16 | 17 |
| Tax % | 30% | 31% | 28% | 30% | 32% | 28% | 30% | 21% | 31% | 30% | 27% | 8% | 26% |
| Net Profit + | 10 | 14 | 11 | 13 | 10 | 15 | 12 | 13 | 8 | 11 | 9 | 15 | 13 |
| EPS in Rs | 1.25 | 1.69 | 1.44 | 1.56 | 1.21 | 1.81 | 1.49 | 1.57 | 0.94 | 1.29 | 1.14 | 1.78 | 1.55 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript